Evaluation of patients’ adherence to statins in Poland

References

• Concise Statistical Yearbook of Poland 2008. Central Statistical Office. Zakład wydawnictw statystycznych, Warszawa 2008. Available at: www.stat.gov.pl [Last accessed 30 November 2009]
   Google Scholar
• Endo A, Tsujita Y, Kuroda M, et al. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutarylcoenzyme A reductase. Eur J Biochem 1977;77:31-36
   PubMedGoogle Scholar
• Grundy SM. Consensus statement: role of therapy with ‘statins’ in patients with hypertriglyceridemia. Am J Cardiol 1998;81(Suppl. 1A):1B-6B
   Google Scholar
• Davis ME, Harrison DG. Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating endothelial cell nitric oxide production. Circulation 2001;1:2-4
   Google Scholar
• Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003;63:1821-54
   PubMed Web of Science ®Google Scholar
• Kwak B. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65
   PubMed Web of Science ®Google Scholar
• The CARE Study Group. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9
   PubMed Web of Science ®Google Scholar
• The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin Study (4S). Lancet 1994;344:1383-13894
   PubMed Web of Science ®Google Scholar
• Wei L, Flynn R, Murray GD, et al. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment? Pharmacoepidemiol Drug Saf 2004;13:761-66
   PubMed Web of Science ®Google Scholar
• Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow-up study. Heart 2002;88:229-33
   PubMed Web of Science ®Google Scholar
• The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
   Google Scholar
• MacMohn S, Sharpe N, Gamble G, et al. on behalf of the LIPID Trial Research Group. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis Substudy. Circulation 1998;97:1784-90
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9
   PubMed Web of Science ®Google Scholar
• Seruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary ballon angioplasty. Final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999;20:58-69
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Ho MP, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization, 2003. ISBN 924 154599 2
   Google Scholar
• DiMatteo MR, DiNicola DD. Achieving patient compliance. New York: Pergamon, 1982
   Google Scholar
• Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence. A summary of the literature. Med Care 2004;7:649-52
   Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care 1986;24:67-74
   PubMed Web of Science ®Google Scholar
• Norell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med E Med Psychol 1981;15:57-61
   Web of Science ®Google Scholar
• Guerrero D, Rudd P, Bryant-Kosling C, et al. Antihypertensive medication-taking. Investigation of a simple regimen. Am J Hypertens 1993;6:586-92
   PubMed Web of Science ®Google Scholar
• Lee JY, Kusek JW, Greene PE, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney disease and hypertension (AASK) pilot study. Am J Hypertens 1996;9:719-25
   PubMed Web of Science ®Google Scholar
• Waeber B, Burnier M, Brunner HR. The problem of compliance with antihypertensive therapy. In: Mancia G. (ed.) Manual of Hypertension. London: Churchill Livingstone, 2002
   Google Scholar
• Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
   PubMed Web of Science ®Google Scholar
• Krigsman K, Melander A, Carlsen A, et al. Refill non-adherence to repeat prescriptions leads to treatment gaps or to high extra costs. Pharm World Sci 2007;29:19-24
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;1:105-16
   Google Scholar
• National Health Fund – Lubuski Oddział Wojewódzki Narodowego Funduszu Zdrowia. Available at: www.nfz-zielonagora.pl [Last accessed 30 August 2010]
   Google Scholar
• Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52
   PubMed Web of Science ®Google Scholar
• Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diab Care 2004;27:2149-53
   PubMed Web of Science ®Google Scholar
• Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: Compliance study 1993–1998. Br J Clin Pharmacol 2001;53:375-8
   Web of Science ®Google Scholar
• Abraha I, Montedori A, Stracci F, et al. Statin compliance in the Umbrian population. Eur J Clin Pharmacol 2003;59:659-61
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 1998;279:1458-62
   Google Scholar
• Campione JR, Sleath B, Biddle AK, et al. The influence of physicians’ guideline compliance on patients’ statin adherence: A retrospective cohort study. Am J Geriatr Pharmacother 2005;3:229-39
   PubMedGoogle Scholar
• Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001;19:149-55
   PubMed Web of Science ®Google Scholar
• Morningstar BA, Sketris IS, Kephart GC, et al. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Therapeut 2002;27:213-20
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar